Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition
- PMID: 31047013
- PMCID: PMC6916648
- DOI: 10.1016/j.jacc.2019.01.066
Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition
Similar articles
-
Mek Inhibitor Reverses Hypertrophic Cardiomyopathy in RIT1 Mutated Noonan Syndrome: For the first time, hypertrophic cardiomyopathy was reversed in Noonan syndrome associated with a RIT1 mutation.Am J Med Genet A. 2019 Aug;179(8):1408-1409. doi: 10.1002/ajmg.a.40456. Am J Med Genet A. 2019. PMID: 31355539 No abstract available.
-
Normal pregnancy in a case of Noonan syndrome with hypertrophic cardiomyopathy.J Assoc Physicians India. 1996 Jul;44(7):494-5. J Assoc Physicians India. 1996. PMID: 9282616 No abstract available.
-
MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept.Can J Cardiol. 2024 May;40(5):789-799. doi: 10.1016/j.cjca.2024.02.020. Epub 2024 Mar 1. Can J Cardiol. 2024. PMID: 38432396 Review.
-
MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease.Genes (Basel). 2021 Dec 21;13(1):6. doi: 10.3390/genes13010006. Genes (Basel). 2021. PMID: 35052347 Free PMC article.
-
[Modern genetic counselling : Practical aspects exemplified by hypertrophic cardiomyopathy].Internist (Berl). 2018 Aug;59(8):790-798. doi: 10.1007/s00108-018-0452-z. Internist (Berl). 2018. PMID: 29943241 Review. German.
Cited by
-
Preclinical evaluation of CRISPR-based therapies for Noonan syndrome caused by deep-intronic LZTR1 variants.Mol Ther Nucleic Acids. 2024 Jan 23;35(1):102123. doi: 10.1016/j.omtn.2024.102123. eCollection 2024 Mar 12. Mol Ther Nucleic Acids. 2024. PMID: 38333672 Free PMC article.
-
Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.Am J Med Genet A. 2020 Apr;182(4):866-876. doi: 10.1002/ajmg.a.61485. Epub 2020 Jan 8. Am J Med Genet A. 2020. PMID: 31913576 Free PMC article.
-
Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes.Front Pediatr. 2021 Feb 25;9:632293. doi: 10.3389/fped.2021.632293. eCollection 2021. Front Pediatr. 2021. PMID: 33718303 Free PMC article. Review.
-
Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib.Life (Basel). 2024 Jun 6;14(6):731. doi: 10.3390/life14060731. Life (Basel). 2024. PMID: 38929714 Free PMC article. Review.
-
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.Sci Adv. 2023 Jul 14;9(28):eadf4766. doi: 10.1126/sciadv.adf4766. Epub 2023 Jul 14. Sci Adv. 2023. PMID: 37450595 Free PMC article.
References
-
- Wilkinson JD, Lowe AM, Salbert BA et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J 2012;164:442–8. - PubMed
-
- Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiography. 2009;22:709–14. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources